Literature DB >> 12654443

Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial.

C A M Marijnen1, I D Nagtegaal, E Kapiteijn, E Klein Kranenbarg, E M Noordijk, J H J M van Krieken, C J H van de Velde, J W H Leer.   

Abstract

PURPOSE: Circumferential resection margin (CRM) involvement is a prognostic factor for local recurrence in rectal cancer. In a randomized trial comparing preoperative radiotherapy (5 x 5 Gy), followed by total mesorectal excision (TME) with TME alone, we demonstrated the beneficial effect of short-term preoperative radiotherapy on local recurrences. Here we evaluate the effect of radiotherapy on local recurrence rates in patients with different CRM involvements. METHODS AND MATERIALS: Circumferential margins were defined as positive (< or =1 mm), narrow (1.1-2 mm), or wide (>2 mm). Postoperative radiotherapy was mandatory for surgery-only patients with a positive CRM, but was not always administered and enabled us to compare local recurrence rates for patients with or without postoperative radiotherapy. Furthermore, the effect of preoperative radiotherapy was assessed in the different margin groups.
RESULTS: Of 120 patients in the surgery-only group with a positive CRM, 47% received postoperative radiotherapy. There was no difference in the local recurrence rate between the irradiated and nonirradiated patients (17.3% vs. 15.7%, p = 0.98). Preoperative radiotherapy was effective in patients with a narrow CRM (0% vs. 14.9%, p = 0.02) or wide CRM (0.9 vs. 5.8%, p < 0.0001), but not in patients with positive margins (9.3% vs. 16.4%, p = 0.08).
CONCLUSION: Preoperative hypofractionated radiotherapy has a beneficial effect in patients with wide or narrow resection margins, but cannot compensate for microscopically irradical resections resulting in positive margins.

Entities:  

Mesh:

Year:  2003        PMID: 12654443     DOI: 10.1016/s0360-3016(02)04291-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  60 in total

1.  Adjuvant treatment of rectal cancer: improving patient selection.

Authors:  Jean-François Bosset
Journal:  Gastrointest Cancer Res       Date:  2008-01

Review 2.  Patterns of local recurrence in rectal cancer after a multidisciplinary approach.

Authors:  Jose M Enríquez-Navascués; Nerea Borda; Aintzane Lizerazu; Carlos Placer; Jose L Elosegui; Juan P Ciria; Adelaida Lacasta; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

Review 3.  Laparoscopic rectal cancer surgery: where do we stand?

Authors:  Mukta K Krane; Alessandro Fichera
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

4.  A novel risk-adjusted nomogram for rectal cancer surgery outcomes.

Authors:  Maria C Russell; Y Nancy You; Chung-Yuan Hu; Janice N Cormier; Barry W Feig; John M Skibber; Miguel A Rodriguez-Bigas; Heidi Nelson; George J Chang
Journal:  JAMA Surg       Date:  2013-08       Impact factor: 14.766

5.  DCE-MRI time-intensity curve visual inspection to assess pathological response after neoadjuvant therapy in locally advanced rectal cancer.

Authors:  Antonella Petrillo; Roberta Fusco; Mario Petrillo; Vincenza Granata; Francesco Bianco; Massimiliano Di Marzo; Paolo Delrio; Fabiana Tatangelo; Gerardo Botti; Biagio Pecori; Antonio Avallone
Journal:  Jpn J Radiol       Date:  2018-07-23       Impact factor: 2.374

6.  Revised tumor and node categorization for rectal cancer based on surveillance, epidemiology, and end results and rectal pooled analysis outcomes.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

Review 7.  Advances in radiotherapy in operable rectal cancer.

Authors:  Aravind Suppiah; John E Hartley; John R T Monson
Journal:  Dig Surg       Date:  2009-06-03       Impact factor: 2.588

8.  Total mesorectal excision for rectal cancer in an unselected population: quality assessment in a low volume center.

Authors:  Floris T J Ferenschild; Imro Dawson; Johannes H W de Wilt; Eelco J R de Graaf; Richard P R Groenendijk; Geert W M Tetteroo
Journal:  Int J Colorectal Dis       Date:  2009-06-02       Impact factor: 2.571

9.  Colorectal Cancer Association of Canada consensus meeting: raising the standards of care for early-stage rectal cancer.

Authors: 
Journal:  Curr Oncol       Date:  2009-12       Impact factor: 3.677

10.  Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).

Authors:  S W Gollins; S Myint; S Susnerwala; B Haylock; M Wise; C Topham; L Samuel; R Swindell; J Morris; L Mason; E Levine
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.